Northwest Biotherapeutics Inc (NWBO) USD0.001
Sell:$0.32Buy:$0.32
$0.01
(3.64%)
- This stock can be held in a
Stocks and Shares ISA$0.01
(3.64%)$0.01
(3.64%)Company Information
About this company
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.
Key people
Key facts
- EPICNWBO
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS66737P6007
- Market cap$497.89m
- Employees25
- Shares in issue1.39bn
- ExchangeOver The Counter
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.